Skip to main content
OpenTrials
Completed

NCT Number: NCT00731341

Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata

The purpose of the current study is to evaluate the technical success, safety and procedure feasibility of hysteroscopic cryoablation treatment of symptomatic uterine fibroids in women who do not desire further pregnancies using Galil Medical's 17-gauge 400mm Argon-based cryoablation needles

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Uterine Fibroids Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Hemorrhage Leiomyoma Menorrhagia Menstruation Disturbances Neoplasms Neoplasms by Histologic Type Neoplasms, Connective and Soft Tissue Neoplasms, Muscle Tissue Pathologic Processes Pathological Conditions, Signs and Symptoms Urogenital Diseases Uterine Diseases Uterine Hemorrhage

Age range

30 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

St.Lucas Andreas Ziekenhuis

Amsterdam, Netherlands

About this study

Currently there are no optimal methods for treating symptomatic uterine fibroids. Existing therapeutic options are conservative (medications), invasive (e.g., hysterectomy, surgical myomectomy), or minimally invasive (uterine artery embolization, or myolysis).

Fibroid ablation using cryogenic energy, known as Cryoablation, offers a potential alternative method of fibroid treatment. Cryotherapy is a well-established technique for the treatment of various benign and malignant conditions. Cryoablation has been described for the treatment of prostate cancer, renal cell carcinoma, liver tumors and benign and malignant breast tumors.

Galil Medical's proposed feasibility study is looking to examine the technical success, safety and feasibility of a hysteroscopic approach for the treatment of symptomatic fibroids. This technique involves the insertion and placement of Galil Medical's 17-gauge cryoablation needle(s)guided by a hysteroscopic device. Ultrasound provides real-time monitoring of the needle insertion, placement and iceball propagation during the cryoablation procedure.

This treatment offers the patient to preserve her uterus by a minimally invasive procedure. The type of the fibroids intended for treatment (Type II submucous myomas)are often very difficult to completely and safely remove hysteroscopically and are often treated through an open or laparoscopic procedure. A hysteroscopic procedure does not involve intraperitoneal intervention and is therefore expected to be associated with less intra-operative and post-operative complications.

The recovery from hysteroscopic cryoablation is expected to be fast with only minimal self resolving discomfort. The patient should be able to return to her normal activity within 24-48 hours.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary complaint is excessive bleeding
  • Subject is able to understand and give informed consent for participation in the study
  • Pre-menopausal woman between the ages of 30 and 50 (inclusive)
  • Has completed childbearing and not contemplating future fertility
  • Has symptomatic uterine fibroids
  • Fibroids type, size, location and number
  • 1 submucosal fibroid
  • Type I and Type II fibroids
  • 2 to 4cm
  • Using contraception to prevent pregnancy

Exclusion criteria

  • Any evidence of known or suspected infection or pre-malignancy/malignancy
  • Desire for future child bearing
  • Fibroids
  • Size > 4cm
  • 2 or more submucosal fibroids
  • Fibroid distance from the serosa is less than 1 cm

Treatment and study plan

Cryoablation for the treatment of uterine fibroids

Procedure

Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.

Other names: Presice Cryoablation System, 17-gauge IceBulb™ needle Lot G3021

Primary outcomes

  1. Number of Adverse Events

    Time frame: up to 4 weeks post procedure.

    Safety of the procedure will be assessed by incidence and severity of intra and post procedure related adverse events (AEs)

Secondary outcomes

  1. Hysteroscopic Cryoablation Related Pain Will be Measured by Self Reported Pain Severity Visual Analogue Scale (VAS) Completed by the Patient

    Time frame: Prior to hospital discharge (less than 24 hours post-procedure)

    Hysteroscopic cryoablation related pain will be measured by self reported pain severity Visual Analogue Scale (VAS) from a scale of 1 (no pain) to 10 (very severe pain) completed by the patient

  2. Time (in Days) to Return to Normal Activity

    Time frame: 4 weeks post procedure

    The number of days needed to return to normal activity was assessed by the participant and reported to the investigator. The response was documented at follow-up.

  3. Number of Participants Discharged on Day of Cryoablation Procedure.

    Time frame: Post procedure

    Per the protocol, this outcome intended to report the average duration of post operative hospital stay. However, this measurement was made very generally and was not collected in number of hours, only the dates were collected. The only actual data that can be stated is that all subjects were discharged from the hospital on the same day as the procedure. In order to report the average length of hospital stay, the wording on the outcome measure title has been changed.

  4. Evaluation of Length of an Average Cryoablation Procedure

    Time frame: Post procedure

    Evaluation of length of an average cryoablation procedure for the treatment of uterine fibroids

  5. Physician's Satisfaction From the Ease and Convenience of the Cryoablation Procedure

    Time frame: Post procedure

    Physician's satisfaction from the ease and convenience of the cryoablation procedure using a scale of 1 (very satisfied) to 5 (very dissatisfied).

Sponsors and collaborators

Lead sponsor

Boston Scientific Corporation

Industry

Registry information

Official study title

Feasibility Study of Hysteroscopic Cryoablation Treatment of Symptomatic Uterine Fibroids in Women Who do Not Desire Further Pregnancies

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Aug 11, 2008
Registry last updated
Jul 19, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.